TY - JOUR
T1 - Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia
T2 - A metaphase-FISH study
AU - El-Rifai, Wa'el
AU - Ruutu, Tapani
AU - Vettenranta, Kim
AU - Temtamy, Samia
AU - Knuutila, Sakari
PY - 1996/1/1
Y1 - 1996/1/1
N2 - Metaphase-FISH was adopted for the detection of proliferating Philadelphia-positive (Ph+) residual leukaemic cells in 25 patients with chronic myeloid leukaemia treated with allogeneic bone marrow transplantation (BMT). Patients were followed up during their clinical remission for 4-50 months (median 17 months) after BMT. 80 bone marrow samples were studied. For most of the cases no fewer than 1000 metaphases were analysed. Six patients (24%) showed residual Ph+ cells during the first 6 months and two others by the end of the first year after BMT. Three patients relapsed during the study and in two of them residual Ph+ cells were detected during the first 6 months after BMT. In 17 patients no Ph+ cells were detected at any stage of follow-up and 16 (94.1%) of them continue in complete clinical and haematological remission. Our results indicate that metaphase-FISH is a reliable tool in the quantitation of proliferating residual leukaemic cells. We suggest that consecutive findings of equal amounts of residual leukaemic cells do not necessarily predict a relapse. However, their presence calls for follow-up at shorter intervals where an increasing number of these cells predicts an ensuing relapse.
AB - Metaphase-FISH was adopted for the detection of proliferating Philadelphia-positive (Ph+) residual leukaemic cells in 25 patients with chronic myeloid leukaemia treated with allogeneic bone marrow transplantation (BMT). Patients were followed up during their clinical remission for 4-50 months (median 17 months) after BMT. 80 bone marrow samples were studied. For most of the cases no fewer than 1000 metaphases were analysed. Six patients (24%) showed residual Ph+ cells during the first 6 months and two others by the end of the first year after BMT. Three patients relapsed during the study and in two of them residual Ph+ cells were detected during the first 6 months after BMT. In 17 patients no Ph+ cells were detected at any stage of follow-up and 16 (94.1%) of them continue in complete clinical and haematological remission. Our results indicate that metaphase-FISH is a reliable tool in the quantitation of proliferating residual leukaemic cells. We suggest that consecutive findings of equal amounts of residual leukaemic cells do not necessarily predict a relapse. However, their presence calls for follow-up at shorter intervals where an increasing number of these cells predicts an ensuing relapse.
KW - Chronic myeloid leukaemia
KW - Minimal residual disease
KW - Nuorescence in situ hybridization
UR - http://www.scopus.com/inward/record.url?scp=0030026450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030026450&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.1996.d01-1507.x
DO - 10.1046/j.1365-2141.1996.d01-1507.x
M3 - Article
C2 - 8603001
AN - SCOPUS:0030026450
VL - 92
SP - 365
EP - 369
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -